CDMOs investigate how to support GLP-1 manufacturing, pharma considers supply chain diversity: #Jefferies23

17 Nov 2023
endpts.com
Vaccine
If there were two key ideas that sprung from the CDMO panel at this week’s Jefferies London Healthcare Conference, it is that manufacturers are reviewing how they can expand into GLP-1s and that securing supply chains is at the back of mind for clients.
There is booming demand for GLP-1s to the point that Sylke Hassel, CEO of API manufacturer Axplora, said that it’s akin to the surge of demand for Covid vaccines during the height of the pandemic.
CDMOs investigate how to support GLP-1 manufacturing, pharma considers supply chain diversity: #Jefferies23
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.